Evicenter
MarkdownMedical informationP&T meetings
Descartes-08

Generalized myasthenia gravis

Launch
Not announced
Last updated
177 sources

Executive summary

Burden of Generalized myasthenia gravis

1 evidence topic · 24 sources

Summary
  • Incidence and prevalence: In a U.S. claims and electronic health records database, the diagnosed prevalence and incidence of myasthenia gravis (MG) in the United States in 2021 were 37.0 per 100,000 persons and 3.1 per 100,000 persons. In 2017 MarketScan data, the age- and sex-standardized incidence was 68.5 new cases per million person-years and the adjusted prevalence 316.4 per million in the commercially and Medicare-insured cohort, and 49.7 per million person-years and 203.7 per million in the Medicaid-insured cohort; the authors estimated approximately 82,715 U.S. adults living with MG in 2021 (320.2 cases per million adults). Among Medicare fee-for-service beneficiaries aged 65 years and older, incidence increased from 12.2 to 13.3 per 100,000 person-years from 2008–2009 to 2018–2019, and period prevalence from 81 to 119 per 100,000 from 2006–2007 to 2018–2019. The ICER budget impact inputs yielded 46,870 patients with generalized MG (gMG) in MGFA clinical classes II to IV.
  • Generalized disease and antibody status: About 80% of patients progress to some form of generalized disease, typically within the first two years of symptom onset, and approximately 80% of patients with gMG have AChR autoantibodies. In 20% of patients with MG, weakness remains confined to the extraocular muscles. In a cohort of 220 participants diagnosed with gMG, 84% were anti-AChR positive, 6% anti-MuSK positive, and 10% seronegative.
  • Myasthenic crisis and exacerbations: Myasthenic crisis, defined by respiratory insufficiency requiring invasive or non-invasive ventilation, occurs in approximately 15% to 20% of patients with MG, usually within the first 2 to 3 years of the disease, and mortality in U.S. cohorts is less than 5%. Approximately 20% of patients with gMG are estimated to experience a crisis over a period of 3 years or longer, and approximately one third experience myasthenic exacerbations within any given year. Among 16,561 gMG patients (12,813 prevalent and 3748 incident), exacerbation occurred during follow-up in 12.2% and 22.0% and myasthenic crisis in 6.0% and 12.4%. In one cohort, crisis occurred in 8.9% of individuals, with a 30-day mortality of 28.1%; 5-year overall survival was 75% overall and 39% among those with crisis.
  • Hospitalization and mortality: Among 19,715 adult patients with 56,822 admissions, hospitalization rates increased from 2010 to 2019 at an average annualized rate of 4.9% (6.8% for MG crisis), readmission rates were approximately 20% in each year, and in-hospital mortality averaged 1.8% overall and 5.0% among patients aged 65 years or older. In another inpatient analysis, in-hospital mortality was 2.2% overall and 4.47% in MG crisis. Among Medicare fee-for-service beneficiaries aged 65 years and older with MG, all-cause mortality was 6.26 deaths per 100 person-years in 2006–2007 and 5.67 in 2018–2019 (p = 0.18). In a cohort of 6024 incident MG and 30,083 control beneficiaries, mortality was 66.8 versus 57.1 per 1000 person-years; after adjustment for time-varying comorbidity, the adjusted hazard ratio was 1.09 (0.87 to 1.36), and 16% of deaths in the MG cohort were attributed to MG.
  • Symptoms and quality of life: In interviews with 28 individuals with gMG in the United States, participants reported an average of 16 symptoms; the most frequent were eyelid drooping (93%), physical fatigue (89%), and symptoms affecting the legs, difficulty breathing, and difficulty holding the head up (82% each). 96% reported fluctuations in symptoms and severity, and all reported emotional impacts and impacts on work and finances. Among 841 participants from seven countries, mean baseline EQ-5D-5L utility was 0.817, 0.766, 0.648, and 0.530 for MGFA classes I to IV. Among 1,859 respondents (58.4% with moderate-to-severe MG), mean EQ-5D-5L utility was 0.739 versus 0.843 in the POPUP comparison sample; 34.4% versus 13.2% of the general population reported sick leave in the past month, and 34.8% versus 8.3% reported needing help from a caregiver. In the MyRealWorld-MG study, 11.4% reported stopping work or retiring early due to MG, and patients with severe MG incurred 3.8 times more productivity losses than patients with mild disease.
  • Economic burden: Among adults with newly diagnosed gMG in Komodo Research data (January 1, 2017, to September 30, 2023), mean annual all-cause total health care costs were $58,341 versus $14,469 in a non-MG cohort (difference $43,872), and 59.3% of the difference was driven by pharmacy costs, mostly immunoglobulin. Among 16,561 gMG patients, costs were $5420 per patient per month (about $65,000 per annum) versus $1298 (about $15,500 per annum) for non-gMG controls, and $17,113 and $18,640 per patient per month in patients with exacerbation and crisis. In matched cohorts of 2,739 patients each, mean incremental healthcare costs associated with MG were $4,155 ($5,567 versus $1,411), and mean monthly costs in the exacerbation or crisis subgroup (n = 419) were $17,330. Patients with a clinical event had mean total healthcare costs of $95,821 versus $25,029 for those without. All-cause costs were $173,956.99 in the 12 months after a crisis index date. The difference-in-difference estimates of total health care cost for an MG diagnosis were $25,799 in commercial and $4,927 in Medicare patients. Among 8833 patients with gMG, annual all-cause costs were $76,381 with any glucocorticoid use and $35,309 without. Median annual MG-related costs were $81,900 in a chronic IVIg cohort, $30,300 in a multiple nonsteroidal immunosuppressant cohort, and $2540 in the reference cohort. Among 800 people with MG and 238 caregivers, 70% reported making financial adjustments or seeking financial assistance, and annual out-of-pocket costs had a mean of $15,798 and a median of $7750.